ATYRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
aTYR PHARMA INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$0.17−0.00 (-1.32%)
Close on Oct 19, 2026
- Market cap
- $16.84M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$0.8483 (−83.17%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
aTYR PHARMA INC saw revenue fall 19.1% to $190.00K over fiscal 2025. Free cash flow was -$54.82M.
Revenue
$190.00K
-19.1% vs. a year earlier
Operating income
-$63.86M
TTM Q2 2026
Free cash flow
-$54.82M
TTM Q2 2026
EPS, diluted
-$0.62
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- $16.84M
- P/E ratio
- –
- Price to sales
- 88.62
- Price to book
- 0.35
- Dividend yield
- –
- Free cash flow yield
- -325.56%
Fundamentals
- Revenue
- $190.00K
- Net income
- -$60.81M
- EPS, diluted
- -$0.62
- Free cash flow
- -$54.82M
- Book value per share
- $0.50
- Diluted shares
- 98M
Fourteen years at a glance
Fiscal years 2012 to 2025 and trailing twelve months, USD
Revenue
–
Operating income
-$63.86M
Net income
-$60.81M
EPS, diluted
-$0.62
Free cash flow
-$54.82M
Reported periodTrailing twelve months